JP5624766B2 - アルコールを含まないアルガトロバン製剤 - Google Patents
アルコールを含まないアルガトロバン製剤 Download PDFInfo
- Publication number
- JP5624766B2 JP5624766B2 JP2009530403A JP2009530403A JP5624766B2 JP 5624766 B2 JP5624766 B2 JP 5624766B2 JP 2009530403 A JP2009530403 A JP 2009530403A JP 2009530403 A JP2009530403 A JP 2009530403A JP 5624766 B2 JP5624766 B2 JP 5624766B2
- Authority
- JP
- Japan
- Prior art keywords
- salt
- argatroban
- formulation
- pharmaceutically acceptable
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84755606P | 2006-09-27 | 2006-09-27 | |
| US60/847,556 | 2006-09-27 | ||
| US85072506P | 2006-10-11 | 2006-10-11 | |
| US60/850,725 | 2006-10-11 | ||
| PCT/US2007/020725 WO2008039473A2 (en) | 2006-09-27 | 2007-09-26 | Alcohol free formulation of argatroban |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010504971A JP2010504971A (ja) | 2010-02-18 |
| JP2010504971A5 JP2010504971A5 (enExample) | 2013-04-18 |
| JP5624766B2 true JP5624766B2 (ja) | 2014-11-12 |
Family
ID=39230808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009530403A Active JP5624766B2 (ja) | 2006-09-27 | 2007-09-26 | アルコールを含まないアルガトロバン製剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7589106B2 (enExample) |
| EP (1) | EP2083823A4 (enExample) |
| JP (1) | JP5624766B2 (enExample) |
| CA (1) | CA2669727C (enExample) |
| WO (1) | WO2008039473A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7915290B2 (en) * | 2008-02-29 | 2011-03-29 | Baxter International Inc. | Argatroban formulations and methods for making and using same |
| WO2012054831A2 (en) | 2010-10-21 | 2012-04-26 | Rtu Pharmaceuticals, Llc | Ready to use ketorolac formulations |
| EP2884963B1 (en) * | 2012-08-15 | 2017-12-27 | Yung Shin Pharm. Ind. Co. Ltd. | Stable pharmaceutical formulation of cabazitaxel |
| US9636376B2 (en) | 2012-09-11 | 2017-05-02 | Innopharma, Inc. | Stable compositions of peptide epoxy ketones |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5214052A (en) | 1987-07-28 | 1993-05-25 | Mitsubishi Kasei Corporation | Method for dissolving arginineamides and pharmaceutical compositions containing them |
| US5506241A (en) | 1992-03-18 | 1996-04-09 | Mitsubishi Chemical Corporation | Argatroban preparations for ophthalmic use |
| JPH06219949A (ja) | 1993-01-25 | 1994-08-09 | Mitsubishi Kasei Corp | 抗トロンビン剤及びその製造方法 |
| JPH06219948A (ja) | 1993-01-25 | 1994-08-09 | Mitsubishi Kasei Corp | 抗トロンビン剤及びその製造方法 |
| JPH07228532A (ja) * | 1993-04-22 | 1995-08-29 | Senju Pharmaceut Co Ltd | 水性液剤、その有効成分の溶解性向上方法および安定化方法 |
| EP0621036B1 (en) | 1993-04-22 | 1999-03-17 | Senju Pharmaceutical Co., Ltd. | Aqueous compositions comprising argatroban and cyclodextrin or caffeine |
| FR2715566B1 (fr) * | 1994-02-03 | 1996-03-08 | Synthelabo | Solutions aqueuses concentrées d'argatroban. |
| EP1117398A2 (en) | 1998-09-28 | 2001-07-25 | Merck & Co., Inc. | A method for treating inflammatory diseases by administering a thrombin inhibitor |
| US6495534B2 (en) * | 2000-05-15 | 2002-12-17 | Pharmacia & Upjohn Spa | Stabilized aqueous suspensions for parenteral use |
| ATE427948T1 (de) | 2001-04-24 | 2009-04-15 | Purdue Research Foundation | Folat-mimetika und deren folatrezeptorbindende konjugate |
| WO2004026252A2 (en) | 2002-09-23 | 2004-04-01 | The Regents Of The University Of Michigan | Glioma treatments |
| ATE514416T1 (de) | 2005-09-01 | 2011-07-15 | Baxter Internat Inc A Delaware Corp | Argatrobanformulierung mit einer säure als lösungsvermittler |
-
2007
- 2007-09-26 WO PCT/US2007/020725 patent/WO2008039473A2/en not_active Ceased
- 2007-09-26 EP EP07861374A patent/EP2083823A4/en not_active Ceased
- 2007-09-26 JP JP2009530403A patent/JP5624766B2/ja active Active
- 2007-09-26 US US11/904,067 patent/US7589106B2/en active Active
- 2007-09-26 CA CA2669727A patent/CA2669727C/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2669727C (en) | 2014-10-28 |
| WO2008039473A2 (en) | 2008-04-03 |
| US20080076798A1 (en) | 2008-03-27 |
| EP2083823A2 (en) | 2009-08-05 |
| JP2010504971A (ja) | 2010-02-18 |
| US7589106B2 (en) | 2009-09-15 |
| CA2669727A1 (en) | 2008-04-03 |
| EP2083823A4 (en) | 2010-01-13 |
| WO2008039473A3 (en) | 2008-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO1999002158A1 (ja) | 4,5−エポキシモルヒナン誘導体を含有する安定な医薬品組成物 | |
| JP2017514924A (ja) | シクロホスファミド液状濃縮物の製剤 | |
| CN107810000B (zh) | 来氟米林的可注射药物组合物 | |
| JP5624766B2 (ja) | アルコールを含まないアルガトロバン製剤 | |
| US7094414B2 (en) | Famotidine injections | |
| TW201836609A (zh) | 包含硼替佐米(bortezomib)之穩定調配物及其製備方法 | |
| JP6347784B2 (ja) | 神経筋遮断薬の安定化水性組成物 | |
| CN115666579A (zh) | 卡非佐米的稳定的即稀释型制剂 | |
| JP2010504971A5 (enExample) | ||
| JP3781308B2 (ja) | アルギニンアミド類を含有する医薬製剤 | |
| JPH0576929B2 (enExample) | ||
| JP2001163776A (ja) | 安定化された液剤 | |
| WO2008045410A2 (en) | Alcohol free formulation of argatroban | |
| US20130023559A1 (en) | Alcohol free formulation of argatroban | |
| JPH11228404A (ja) | 安定な水性点眼剤 | |
| CN101516370A (zh) | 阿加曲班的无醇制剂 | |
| AU2008250717A1 (en) | Aqueous pharmaceutical preparation | |
| HK1131895A (en) | Alcohol free formulation of argatroban | |
| WO2019130228A1 (en) | Stable liquid compositions of melphalan | |
| US7687516B2 (en) | Alcohol free formulation of argatroban | |
| WO2004096229A1 (ja) | 溶液医薬組成物 | |
| TW201106961A (en) | Ipamorelin diacetate injection and infusion solutions | |
| JP2628020B2 (ja) | 医薬製剤用水溶液 | |
| TR2021002013A2 (tr) | Injectable composition comprising emoxypine | |
| JP6854710B2 (ja) | ペメトレキセドを含有する注射用溶液製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100903 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121204 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20130304 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131203 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140218 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140225 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140602 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140722 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140813 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140902 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140929 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5624766 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |